Rimegepant is a medicinal product that is in clinical development as an oral tablet for acute treatment of migraine in adults. Rimegepant works by blocking a receptor called calcitonin gene-related peptide (CGRP). This receptor plays an important role in migraine pathophysiology. A migraine is usually a moderate or severe headache felt as a throbbing pain on one side of the head. Many people also have symptoms such as nausea, vomiting and increased sensitivity to light or sound. Migraines may be with aura (specific warning signs just before the migraine begins, such as seeing flashing lights), although the most common type is without aura (no specific warning signs). Migraine is a common health condition, affecting around one in every five women and around one in every 15 men.
Rimegepant potentially offers an alternative to current agents, particularly for patients who have contraindications to the use of triptans. This includes patients with underlying cardiovascular diseases, or who either do not respond or have inadequate or inconsistent response to triptans or are intolerant to them.
Currently there are no approved treatments for CRPS. Neridronic acid administered by injection is currently being developed to treat CRPS and early results indicate that it has the possibility to control the condition. If approved neridronic acid will be a potential new treatment for CRPS.